- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03691441
Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer
May 15, 2023 updated by: Universitätsklinikum Hamburg-Eppendorf
Comparative Effectiveness Trial of Transoral Head and Neck Surgery followed by adjuvant Radio(chemo)therapy versus primary Radiochemotherapy for Oropharyngeal Cancer
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This trial investigates the effectiveness of transoral head and neck surgery (TOS) for locally advanced, but transorally resectable oropharyngeal cancer followed by risk-adapted adjuvant therapy versus primary radiochemotherapy (definitive chemoradiotherapy, CRTX).
Both treatments are internationally accepted standards.
The choice of the treatment strategy depends on the preference of the responsible attending physician and on the country of residence.
Internationally, mostly definitive chemoradiotherapy is regarded as the standard of care for oropharyngeal cancer.
In Germany, however, transoral surgical resection is also well established and commonly practiced.
The key question therefore is whether one of the two therapies is more effective than the other in clinical daily routine under the given conditions of our health care system and with a realistic, non-ideal patient cohort.
For this reason, a comparative effectiveness research (CER) concept will be applied in this setting.
The aim of this trial is primarily to show a superiority of the surgical approach in terms of local and locoregional control and secondarily to compare functional outcome and quality of life.
Study Type
Interventional
Enrollment (Anticipated)
280
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 13353
- Berlin Charité
-
Hamburg, Germany, 20246
- Universitätsklinikum Hamburg Eppendorf
-
-
Baden- Würtemberg
-
Mannheim, Baden- Würtemberg, Germany, 68167
- Universitäts- HNO- Klinik Mannhein
-
-
Baden-Württemberg
-
Karlsruhe, Baden-Württemberg, Germany, 76135
- St. Vincentius- Kliniken Karlsruhe
-
Ulm, Baden-Württemberg, Germany, 89075
- Universitatsklinikum Ulm
-
-
Bayern
-
Dachau, Bayern, Germany, 85221
- Helios Amper- Klinikum Dachau
-
-
Brandenburg
-
Neuruppin, Brandenburg, Germany, 16816
- Ruppiner Klinken GmbH
-
Potsdam, Brandenburg, Germany, 14467
- Klinikum Ernst von Bergmann gemeinnützige GmbH
-
-
Hessen
-
Frankfurt, Hessen, Germany, 60590
- Universitätsklinikum Frankfurt
-
Gießen, Hessen, Germany, 35385
- Universitätsklinikum Gießen
-
Marburg, Hessen, Germany, 35037
- Philipps-Universitat Marburg
-
-
Niedersachsen
-
Stade, Niedersachsen, Germany, 21682
- Elbekliniken Stade- Buxtehude GmbH, Klinikum Stade und Klinik Dr. Hancken
-
Wolfsburg, Niedersachsen, Germany, 38440
- Klinikum Wolfsburg
-
-
Nordrhein-Westfalen
-
Gummersbach, Nordrhein-Westfalen, Germany, 51643
- Kreiskliniken Gummersbach-Waldbröl GmbH Klinik Oberberg
-
Köln, Nordrhein-Westfalen, Germany, 50937
- Universitätsklinikum Köln
-
-
Rheinland-Pfalz
-
Koblenz, Rheinland-Pfalz, Germany, 56073
- Katholischen Krankenhaus Koblenz
-
-
Saarland
-
Homburg, Saarland, Germany, 22421
- Universität des Saarlandes
-
-
Sachsen
-
Leipzig, Sachsen, Germany, 04103
- Universitätsklinik Leipzig / Borna Sana Kliniken Leipziger Land
-
-
Schleswig- Holstein
-
Lübeck, Schleswig- Holstein, Germany, 23538
- Universitätsklinikum Schleswig-Holstein Campus Lübeck
-
-
Thüringen
-
Jena, Thüringen, Germany, 07757
- Universitätsklinikum Jena
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically proven SCC of the oropharynx; T1, N2a-c, M0; T2, N1-2c, M0; T3, N0-2c, M0, with only amendable to transoral resection)
- Primary tumor must be resectable through transoral approach
- p16 immunohistochemitry by local pathology or FFPE tissue must be available for central HPV diagnostic
- Written and signed informed consent
- Briefing through surgeon and radiation oncologist
- ECOG PS ≥2, Karnofsky PS ≥ 60 %
- Age ≥ 18
- Curative treatment intent
- Adequate bone marrow function: leucocytes > 3.0 x 109/L, neutrophils > 1.5 x 109/L, platelets > 80 x 109/L, hemoglobin > 9.5 g/dL
- Adequate liver function: Bilirubin < 2.0 g/dL, SGOT, SGPT, < 3 x ULN
- If of childbearing potential, willingness to use effective contraceptive method for the study duration and 2 months post-dosing.
- dental examination and appropriate dental therapy if needed prior to Confidential TopROC 2017_03_24 Version 1.0 Seite 15 von 124 beginning of radiotherapy
- Nutritional evaluation prior to initiation of therapy and optional prophylactic gastrostomy (PEG) tube placement
Exclusion Criteria:
- Prior invasive malignancy except controlled skin cancer or carcinoma in situ of cervix
- Unknown primary (CUP), nasopharynx, hypopharynx, laryngeal or salivary gland cancer
- Metastatic disease
- Serious co-morbidity, e.g. high-grade carotid artery stenosis, congestive heart failure NYHA grade 3 and 4, liver cirrhosis CHILD C
- Hemoglobin level <9.5g/dl within 4 weeks before randomization
- Pregnancy or lactation
- Women of child-bearing potential with unclear contraception
- Previous treatment with chemotherapy, radiotherapy, EGFR-targeting agents or surgery exceeding biopsy in head and neck
- Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study screening
- Social situations that limit compliance with study requirements or patients with an unstable condition (e.g., psychiatric disorder, a recent history of drug or alcohol abuse, interfering with study compliance, within 6 months prior to screening) or otherwise thought to be unreliable or incapable of complying with the requirements of the protocol
- Patients institutionalized by official means or court order
- Deficient
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Resection/adjuvant radio(-chemo)therapy
|
Definitive surgery should generally be performed within 2 weeks, but not more than 4 weeks after randomization.
The appropriately indicated neck dissection(s) may be performed either prior to, during the same session, or within 2 weeks after the resection of the primary tumor, but not later than 4 weeks following randomization.
The primary tumor is to be resected with clear margins (R0) and en bloc in all cases.
Frozen section assessment must be routinely and readily available.
Other Names:
6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible
The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU.
According to local routine, chemotherapy protocols as listed in study protocol should be used.
|
Active Comparator: Adjuvant radio(-chemo)therapy/salvage neck dissection
|
6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible
The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU.
According to local routine, chemotherapy protocols as listed in study protocol should be used.
+/- Salvage neck dissection 12±2 weeks after treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to local or locoregional failure or death from any cause
Time Frame: Defined as time from randomization up to 36 month
|
The primary objective of this study is to evaluate the effectiveness of primary surgical versus non-surgical treatment of patients with locally advanced, but transorally resectable oropharyngeal cancer in terms of time to local or locoregional failure or death from any cause (LRF).
|
Defined as time from randomization up to 36 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: Until 3 years after randomization
|
Overall survival (OS) in both study arms, follow-up visits until the end of study
|
Until 3 years after randomization
|
Disease-free survival
Time Frame: Until 3 years after randomization
|
Disease-free survival (DFS) in both study arms.
CT- Scans will be performed at month 3, month 6, 18, 30 and in case of suspicion of recurrence
|
Until 3 years after randomization
|
Effectiveness in terms of toxicity
Time Frame: Until 3 years after randomization
|
Effectiveness in terms of toxicity in both study arms.
Monitoring of AE's/SAE's from randomization to 28 days after the last administration of IMP and/or 5 months after randomization in this trial
|
Until 3 years after randomization
|
Effectiveness in terms of morbidity
Time Frame: Until 3 years after randomization
|
Effectiveness in terms of morbidity (including swallowing function by MDADI Score) by late morbidity documentation in both study arms.
|
Until 3 years after randomization
|
Quality of life evaluated by patient
Time Frame: Until 3 years after randomization
|
Quality of life Questionnaires using QLQ H&N-43 in both study arms
|
Until 3 years after randomization
|
Quality of life evaluated by patient
Time Frame: Until 3 years after randomization
|
CareQuality of life Questionnaires using EORTC QLQ-C30 both study arms
|
Until 3 years after randomization
|
Cost-utility
Time Frame: Until 3 years after randomization
|
Cost-utility in both study armsusing Questionnaire Health Care Utilization and Productivity loss.
|
Until 3 years after randomization
|
Cost-effectiveness
Time Frame: Until 3 years after randomization
|
Cost-effectiveness in both study arms using Questionnaire Health Utilization and Productivity loss.
|
Until 3 years after randomization
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tertiary objectives include comparisons of treatment effects between HPV- Status
Time Frame: Up to 36 month
|
Subgroup analysis of HPV-positive and HPV-negative oropharynx carcinoma
|
Up to 36 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Chia-Jung Busch, PD Dr., Universitätsklinikum Hamburg-Eppendorf
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7.
- Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008 Feb 1;26(4):612-9. doi: 10.1200/JCO.2007.14.1713.
- Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006 Feb 10;24(5):736-47. doi: 10.1200/JCO.2004.00.3335. Epub 2006 Jan 9.
- Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, Roberts S. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region. Head Neck. 2013 May;35(5):747-55. doi: 10.1002/hed.22015. Epub 2012 Jan 20.
- Licitra L, Zigon G, Gatta G, Sanchez MJ, Berrino F; EUROCARE Working Group. Human papillomavirus in HNSCC: a European epidemiologic perspective. Hematol Oncol Clin North Am. 2008 Dec;22(6):1143-53, vii-viii. doi: 10.1016/j.hoc.2008.10.002.
- Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014 Oct;12(10):1454-87. doi: 10.6004/jnccn.2014.0142.
- Gregoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v184-6. doi: 10.1093/annonc/mdq185. No abstract available.
- Wegscheider K, Drabik A, Bleich C, Schulz H. [Benefit assessment in health services research and epidemiology]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Mar;58(3):298-307. doi: 10.1007/s00103-014-2106-1. German.
- Lorincz BB, Mockelmann N, Busch CJ, Knecht R. Functional outcomes, feasibility, and safety of resection of transoral robotic surgery: single-institution series of 35 consecutive cases of transoral robotic surgery for oropharyngeal squamous cell carcinoma. Head Neck. 2015 Nov;37(11):1618-24. doi: 10.1002/hed.23809. Epub 2014 Aug 28.
- Boscolo-Rizzo P, Gava A, Baggio V, Marchiori C, Stellin M, Fuson R, Lamon S, Da Mosto MC. Matched survival analysis in patients with locoregionally advanced resectable oropharyngeal carcinoma: platinum-based induction and concurrent chemoradiotherapy versus primary surgical resection. Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):154-60. doi: 10.1016/j.ijrobp.2010.01.032. Epub 2010 Sep 23.
- Hicks WL Jr, Kuriakose MA, Loree TR, Orner JB, Schwartz G, Mullins A, Donaldson C, Winston JM, Bakamjian VY. Surgery versus radiation therapy as single-modality treatment of tonsillar fossa carcinoma: the Roswell Park Cancer Institute experience (1971-1991). Laryngoscope. 1998 Jul;108(7):1014-9. doi: 10.1097/00005537-199807000-00012.
- O'Hara J, MacKenzie K. Surgical versus non-surgical management of early stage oropharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2011 Mar;268(3):437-42. doi: 10.1007/s00405-010-1362-4. Epub 2010 Aug 27.
- Bussmann L, Laban S, Wittekindt C, Stromberger C, Tribius S, Mockelmann N, Bottcher A, Betz CS, Klussmann JP, Budach V, Muenscher A, Busch CJ. Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC). BMC Cancer. 2020 Jul 29;20(1):701. doi: 10.1186/s12885-020-07127-2.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 5, 2018
Primary Completion (Anticipated)
May 5, 2024
Study Completion (Anticipated)
May 5, 2024
Study Registration Dates
First Submitted
March 2, 2018
First Submitted That Met QC Criteria
September 28, 2018
First Posted (Actual)
October 1, 2018
Study Record Updates
Last Update Posted (Actual)
May 17, 2023
Last Update Submitted That Met QC Criteria
May 15, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TopROC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oropharyngeal Cancer
-
Wake Forest University Health SciencesTerminatedHead and Neck Cancer | Stage I Laryngeal Cancer | Stage II Laryngeal Cancer | Stage I Hypopharyngeal Cancer | Stage I Oropharyngeal Cancer | Stage II Hypopharyngeal Cancer | Stage II Oropharyngeal Cancer | Stage III Hypopharyngeal Cancer | Stage III Laryngeal Cancer | Stage III Oropharyngeal Cancer | Stage... and other conditionsUnited States
-
Lisette NixonStanford University; University of Leipzig; AdventHealth; UNICANCER; Princess Alexandra...RecruitingHuman Papillomavirus (HPV)-Positive Oropharyngeal CancerGermany, United Kingdom, United States, Australia, France
-
University of FloridaTerminatedOropharyngeal CancersUnited States
-
Shanghai Jiao Tong University School of MedicineFudan University; Tongji University; Second Military Medical UniversityCompletedOral Cancer | Locally Advanced Malignant Neoplasm | Oropharyngeal CarcinomaChina
-
M.D. Anderson Cancer CenterRecruitingOropharyngeal CarcinomaUnited States
-
NexImmune Inc.Not yet recruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Oropharyngeal Cancer | Human Papilloma Virus | Head and Neck Cancer Metastatic | HPV-Related Squamous Cell Carcinoma | Oropharyngeal Cancer, Metastatic | HPV-Related Mucosal Head and Neck Squamous... and other conditions
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingTongue Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Oropharyngeal Squamous Cell Carcinoma | Stage III Oropharyngeal Squamous Cell CarcinomaUnited States, Canada, Saudi Arabia, Ireland
-
National Cancer Institute (NCI)CompletedLip and Oral Cavity Cancer | Oropharyngeal Cancer | Tongue Cancer | Stage 0 Lip and Oral Cavity Cancer | Stage 0 Oropharyngeal CancerUnited States
-
Shanghai Jiao Tong University School of MedicineFudan University; Tongji University; Second Military Medical UniversityCompletedOral Cancer | Effects of Chemotherapy | Locally Advanced Malignant Neoplasm | Oropharyngeal CarcinomaChina
-
Emory UniversityNational Cancer Institute (NCI)RecruitingClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Oropharyngeal HPV-Positive Squamous Cell CarcinomaUnited States
Clinical Trials on Resection
-
Oslo University HospitalUniversity of Oslo; Helse Stavanger HF; Haukeland University Hospital; St. Olavs... and other collaboratorsRecruitingColorectal Cancer | Liver Metastases | Liver Metastasis Colon Cancer | Colorectal Neoplasms MalignantNorway
-
University of UlmTerminated
-
BUSQUETS, JULINot yet recruiting
-
Southwest Hospital, ChinaUnknown
-
Fudan UniversityUnknownLocal Recurrence of Malignant Tumor of Soft TissueChina
-
Fudan UniversityCompleted
-
Tongji HospitalUnknownNon-muscle Invasive Bladder Cancer
-
Fudan UniversityRecruitingQuality of Life | Gastrointestinal Function | Pregnancy OutcomesChina
-
Changhua Christian HospitalCompletedGastric Subepithelial Tumor
-
Oxford University Hospitals NHS TrustWithdrawn